{"nctId":"NCT01008618","briefTitle":"A Confirmatory Study of Fentanyl in Participants With Osteoarthritis or Low Back Pain","startDateStruct":{"date":"2009-01"},"conditions":["Chronic Pain","Osteoarthritis","Low Back Pain"],"count":218,"armGroups":[{"label":"Fentanyl (Titration period)","type":"EXPERIMENTAL","interventionNames":["Drug: Fentanyl"]},{"label":"Fentanyl (Double-blind period)","type":"EXPERIMENTAL","interventionNames":["Drug: Fentanyl"]},{"label":"Placebo (Double-blind period)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Fentanyl","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants whose pain because of osteoarthritis or low back pain is continuing for at least 12 weeks prior to informed consent\n* Participants who are continuously taking a non-opioid analgesic at the normal highest dose or more for at least 14 consecutive days prior to informed consent, or participant at a certain dose (except the use on an as-needed base) on consecutive days\n* Participants showing insufficient therapeutic efficacy of the non-opioid analgesic currently being used, and requiring a continuous opioid analgesic as per the investigator or sub-investigator\n* Participants with an average pain intensity of 50 millimeter or more on the Visual Analog Scale (VAS) in 24-hour daily living prior to informed consent\n* Participants who can be hospitalized to the 4th day after the initiation of titration period\n\nExclusion Criteria:\n\n* In cases of low back pain, participants with severe pain of lower extremities due to radiculopathy (a problem in which one or more nerves are affected) than that of low back pain, or participants with disc herniation (a medical condition affecting the spine due to trauma, lifting injuries, or idiopathic \\[unknown\\] causes) requiring an operation\n* In cases of low back pain, participants with pain due to compression fracture\n* Participants who had an operation that may affect the assessment within 30 days before informed consent\n* Participants whose main cause of the pain to be assessed is considered attributable to psychogenic pain (physical pain that is caused, increased, or prolonged by mental, emotional, or behavioral factors)\n* Participants with asthma, bradyarrhythmia (slow irregular heart beat) and severe respiratory function disorders","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time From the Initial Day of Application in Double-Blind Period to Withdrawal Because of Insufficient Analgesic Efficacy","description":"Time from start of double-blind (researchers and participants were unaware of the treatment) period to withdrawal because of insufficient analgesic efficacy based on any of the pre-defined discontinuation criteria was noted.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Pain Visual Analog Scale (VAS) Score - Titration Period","description":"The intensity of average pain (degree of pain) felt by the participants in daily living throughout the day on a \"100-millimeter (mm) VAS scale\" by drawing a slash. The left margin (0 mm) was considered \"No pain at all\", and the right margin (100 mm) was considered \"Severer pain than this is inconceivable\". The length (mm) from the left margin to the slash is measured. Mean VAS score during 3 days before the end of Screening period and during 3 days before the end of titration period was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.1","spread":"12.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.71","spread":"21.41"}]}]}]},{"type":"SECONDARY","title":"Pain Visual Analog Scale (VAS) Score - Double-Blind Period","description":"The intensity of average pain (degree of pain) felt by the participants in daily living throughout the day on a \"100-millimeter (mm) VAS scale\" by drawing a slash. The left margin (0 mm) was considered \"No pain at all\", and the right margin (100 mm) was considered \"Severer pain than this is inconceivable\". The length (mm) from the left margin to the slash is measured. Mean VAS score during 3 days before the end of titration period and during 3 days before the end of double-blind period was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":"12.71"},{"groupId":"OG001","value":"29.6","spread":"12.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":"18.99"},{"groupId":"OG001","value":"36.5","spread":"22.29"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Evaluated as Per Participant's Overall Assessment - Titration Period","description":"The participant assessed his/her satisfaction with the therapeutic efficacy by the following 5 grades: \"Extremely satisfied\", \"Satisfied\", \"Neither satisfied nor dissatisfied\", \"Dissatisfied\" and \"Dissatisfied very much\". The results were reported as Category 1 = At least \"Neither satisfied nor dissatisfied\", which included participants with general evaluation of \"Extremely satisfied\" to \"Neither satisfied nor dissatisfied\", and Category 2 = At least \"Satisfied\", which included participants with general evaluation of \"Extremely satisfied\" to \"Satisfied\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"183","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Evaluated as Per Participant's Overall Assessment - Double-Blind Period","description":"The participant assessed his/her satisfaction with the therapeutic efficacy by the following 5 grades: \"Extremely satisfied\", \"Satisfied\", \"Neither satisfied nor dissatisfied\", \"Dissatisfied\" and \"Dissatisfied very much\". The results were reported as Category 1 = At least \"Neither satisfied nor dissatisfied\", which included participants with general evaluation of \"Extremely satisfied\" to \"Neither satisfied nor dissatisfied\", and Category 2 = At least \"Satisfied\", which included participants with general evaluation of \"Extremely satisfied\" to \"Satisfied\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Doses of Rescue Treatment Per Day - Titration Period","description":"If a breakthrough pain occurred or the analgesic efficacy became insufficient, a fast-acting oral morphine was administered. At such instances, one-time dose of the rescue treatment was administered as per the pre-defined criteria. During hospitalization, Investigator, Sub-investigator or Study Collaborator recorded in the medical record and during the out-patient period, the participants were instructed to describe the name of rescue treatment, date and time of treatment, and one-time dose in the participant's diary. The mean number of treatments per day at each assessment time was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.45"}]}]}]},{"type":"SECONDARY","title":"Number of Doses of Rescue Treatment Per Day - Double-Blind Period","description":"If a breakthrough pain occurred or the analgesic efficacy became insufficient, a fast-acting oral morphine was administered. At such instances, one-time dose of the rescue treatment was administered as per the pre-defined criteria. During hospitalization, Investigator, Sub-investigator or Study Collaborator recorded in the medical record and during the out-patient period, the participants were instructed to describe the name of rescue treatment, date and time of treatment, and one-time dose in the participant's diary. The mean number of treatments per day at each assessment time was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.16"},{"groupId":"OG001","value":"0.0","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.49"},{"groupId":"OG001","value":"0.2","spread":"0.42"}]}]}]},{"type":"SECONDARY","title":"Brief Pain Inventory Short Form (BPI-sf) Score - Titration Period","description":"The BPI-sf total score is an average of the pain interference score (mean value for the nine BPI-sf questions \\[questions inquiring about the extent of interference with activities by pain, where the extent is ranked from 0 (does not interfere) to 10 (completely interferes)\\]) and pain subscale score (mean value for the scores for BPI-sf questions 3, 4, 5 and 6 \\[questions inquiring about the extent of pain, where the extent is ranked from 0 (no pain) to 10 (pain as bad as you can imagine)\\]). Total score ranges from 0 to 10 with higher values indicating more pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"1.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"2.19"}]}]}]},{"type":"SECONDARY","title":"Brief Pain Inventory Short Form (BPI-sf) Score - Double-Blind Period","description":"The BPI-sf total score is an average of the pain interference score (mean value for the nine BPI-sf questions \\[questions inquiring about the extent of interference with activities by pain, where the extent is ranked from 0 (does not interfere) to 10 (completely interferes)\\]) and pain subscale score (mean value for the scores for BPI-sf questions 3, 4, 5 and 6 \\[questions inquiring about the extent of pain, where the extent is ranked from 0 (no pain) to 10 (pain as bad as you can imagine)\\]). Total score ranges from 0 to 10 with higher values indicating more pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"1.65"},{"groupId":"OG001","value":"3.2","spread":"1.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"1.83"},{"groupId":"OG001","value":"3.9","spread":"2.08"}]}]}]},{"type":"SECONDARY","title":"Short-Form 36-Item Health Survey Version 2.0 (SF-36v2) - Titration Period","description":"The SF-36v2 is 36-item form related to 8 health concepts (physical functioning, role physical, role emotional, general health, social functioning, bodily pain, vitality, mental health) and 2 summary scores (physical and mental component summary). Physical functioning, role physical and bodily pain contribute to physical component; role emotional, social functioning and mental health contribute to mental component; and social functioning, vitality, and general health contribute to both. All scores are based on a scale from 0 to 100, with higher scores defining more favorable health state.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":"14.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.2","spread":"9.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":"15.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.5","spread":"9.57"}]}]}]},{"type":"SECONDARY","title":"Short-Form 36-Item Health Survey Version 2.0 (SF-36v2) - Double-Blind Period:","description":"The SF-36v2 is 36-item form related to 8 health concepts (physical functioning, role physical, role emotional, general health, social functioning, bodily pain, vitality, mental health) and 2 summary scores (physical and mental component summary). Physical functioning, role physical and bodily pain contribute to physical component; role emotional, social functioning and mental health contribute to mental component; and social functioning, vitality, and general health contribute to both. All scores are based on a scale from 0 to 100, with higher scores defining more favorable health state.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":"14.71"},{"groupId":"OG001","value":"22.8","spread":"14.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.1","spread":"8.29"},{"groupId":"OG001","value":"50.8","spread":"9.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","spread":"16.11"},{"groupId":"OG001","value":"22.5","spread":"14.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.9","spread":"9.82"},{"groupId":"OG001","value":"51.0","spread":"10.41"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Evaluated as Per Physician's Overall Assessment - Titration Period","description":"Physician's global assessment of therapeutic efficacy (effectiveness) of the study drug was measured on a 2-point scale where 1 = effective and 2 = not effective.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Evaluated as Per Physician's Overall Assessment - Double-Blind Period","description":"Physician's global assessment of therapeutic efficacy (effectiveness) of the study drug was measured on a 2-point scale where 1 = effective and 2 = not effective.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":218},"commonTop":["Nausea","Constipation","Somnolence","Vomiting","Dizziness"]}}}